Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity

Leukemia

Volumn 23, Issue 6, 2009, Pages 1087-1097

  Halwachs, S ^a   Schafer I ^a   Seibel, P ^a   Honscha, W ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3,5 DICHLORO 2 PYRIDYLOXY)BENZENE; ANTICONVULSIVE AGENT; BISINDOLYLMALEIMIDE; CALCIUM ION DEPENDENT PROTEIN KINASE C ALPHA; CALCIUM ION DEPENDENT PROTEIN KINASE C DELTA; CARBAMAZEPINE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; METHOTREXATE; OKADAIC ACID; PHENOBARBITAL; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ALPHA; REDUCED FOLATE CARRIER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; DRUG UPTAKE; ENZYME LOCALIZATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION;

EID: 67349204385     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.6     Document Type: Article

References (56)

1. Matherly LH, Goldman ID. Membrane transport of folates. Vitam Horm 2003; 66: 403-456.
2. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000; 356: 285-290.
3. Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J Neurooncol 2000; 48 249-250.
4. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Semin Oncol 2003; 30: 49-52.
5. Ochs JJ, Bowman WP, Pui CH, Abromowitch M, Mason C, Simone JV. Seizures in childhood lymphoblastic leukaemia patients. Lancet 1984; 2 1422-1424.
6. Maytal J, Grossman R, Yusuf FH, Shende AC, Karayalycin G, Lanzkowsky P et al. Prognosis and treatment of seizures in children with acute lymphoblastic leukemia. Epilepsia 1995; 36: 831-836.
7. Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D et al Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992; 84 252-256.
8. Mahoney Jr DH, Shuster JJ, Nitschke R, Lauer S, Steuber CP, Camitta B. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 2000; 18: 1285-1294.
9. Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P et al. Epilepsy and gliomas: Incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998; 17: 479-482.
10. Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997; 24: 30-39.
11. Honscha W, Dötsch KU, Thomsen N, Petzinger E. Cloning and functional characterization of the bile acid-sensitive methotrexate carrier from rat liver cells. Hepatology 2000; 31: 1296-1304.
12. Kneuer C, Honscha KU, Honscha W. Rat reduced-folate carrier-1 is localized basolaterally in MDCK kidney epithelial cells and contributes to the secretory transport of methotrexate and fluoresceinated methotrexate. Cell Tissue Res 2005; 320: 517-524.
13. Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: Relationship to immunophenotype and ploidy. Clin Cancer Res 1998; 4: 2169-2177.
14. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89: 1013-1018.
15. Halwachs S, Kneuer C, Honscha W. Downregulation of the reduced folate carrier transport activity by phenobarbital-type cytochrome P450 inducers and protein kinase C activators. Biochem Biophys Acta 2007; 1768: 1671-1679.
16. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
17. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/ transport by xenobiotics. Arch Pharm Res 2005; 28: 249-268.
18. Tzameli I, Pissios P, Schuetz EG, Moore DD. The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 2000; 20: 2951-2958.
19. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001; 41: 123-143.
20. Siest G, Jeannesson E, Marteau JB, Samara A, Bérangère M, Pfister M et al. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008; 36: 182-189.
21. Hariparsad N. Hepatic and Extra-Hepatic Induction of Drug Metabolizing Enzymes and Drug Transporters by Antiretrovirals, in the Presence and Absence of Viral Infection [Dissertation Doctor of Philosophy]. University of Cincinnati: Cincinnati, 2006.
22. Nguyen TT, Dyer DL, Dunnin DD, Rubin SA, Grant KE, Said HM. Human intestinal folate transport: Cloning, expression, and distribution of complementary RNA. Gastroenterology 1997; 112: 783-791.
23. Carmena D, Sardini A. Lifespan regulation of conventional protein kinase C isotypes. Biochem Soc Trans 2007; 35: 1043-1045.
24. Beck JF, Brügger D, Brischwein K, Liu C, Bader P, Niethammer D et al. Anticancer drug-mediated induction of multidrug resistanceassociated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias. Jpn J Cancer Res 2001; 92: 896-903.
25. Balasubramanian N, Advani SH, Zingde SM. Protein kinase C isoforms in normal and leukemic neutrophils: Altered levels in leukemic neutrophils and changes during myeloid maturation in chronic myeloid leukemia. Leuk Res 2002; 26: 67-81.
26. Alkan S, Huang Q, Ergin M, Denning MF, Nand S, Maududi T et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am J Hematol 2005; 79: 97-106.
27. Jiffar T, Kurinna S, Suck G, Carlson-Bremer D, Ricciardi MR, Konopleva M et al. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 2004; 183: 505-512.
28. Kubitz R, Huth C, Schmitt M, Horbach A, Kullak-Ublick G, Häussinger D. Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells. Hepatology 2001; 34: 340-350.
29. Schrader S, Kneuer C, Honscha W. Alternative transcripts of rat slc19a1: defective sorting and inefficient expression of alternative splicing products - an addendum. DNA Seq 2006; 16: 1-6.
30. Kneuer C, Honscha W. The H(+)-dependent reduced folate carrier 1 of humans and the sodium-dependent methotrexate carrier-1 of the rat are orthologs. FEBS Lett 2004; 566: 83-86.
31. Donato MT, Gomez-Lechon MJ, Castell JV. A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 1993; 213 29-33.
32. Hodges NJ, Orton TC, Strain AJ, Chipman JK. Potentiation of epidermal growth factor- induced DNA synthesis in rat hepatocytes by phenobarbitone: Possible involvement of oxidative stress and kinase activation. Carcinogenesis 2000; 21: 2041-2047.
33. Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 1996; 74: 897-905.
34. Adams PD, Parker PJ. TPA-induced activation of MAP kinase. FEBS Lett 1991; 290: 77-82.
35. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y et al Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett 1998; 429: 179-182.
36. Utesch D, Arand M, Thomas H, Petzinger E, Oesch F. Xenobiotic-metabolizing enzyme activities in hybrid cell lines established by fusion of primary rat liver parenchymal cells with hepatoma cells. Xenobiotica 1992; 22: 1451-1457.
37. Halwachs S, Kneuer C, Honscha W. Endogenous expression of liver-specific drug transporters for organic anions in the rat hepatocytoma fusion cell line HPCT-1E3. Eur J Cell Biol 2005; 84: 677-686.
38. Newton AC. Protein kinase C: Strucitural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001; 101: 2353-2364.
39. Martiny-Baron G, Kazanietzs MG, Mischak H, Blumberg PM, Kochs G, Hug H et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö6976. J Biol Chem 1993; 268: 9194-9197.
40. Wolff NA, Thies K, Kuhnke N, Reid G, Friedrich B, Lang F et al. Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. J Am Soc Nephrol 2003; 8: 1959-1968.
41. Traub LM, Kornfeld S. The trans-Golgi network: A late secretory sorting station. Curr Opin Cell Biol 1997; 9: 527-533.
42. Josting A, Diehl V, Engert A. Methotrexat: Pharmakologie, Toxizität und Rescuemassnahmen bei hochdosierter Behandlung. Der Onkologe 1998; 4: 974-985.
43. Joannard F, Galisteo M, Corcos L, Guillouzo A, Lagadic-Gossmann D. Regulation of phenobarbital-induction of CYP2B and CYP3A genes in rat cultured hepatocytes: Involvement of several serine/threonine protein kinases and phosphatases. Cell Biol Toxicol 2000; 16: 325-337.
44. Marc N, Galisteo M, Lagadic-Gossmann D, Fautrel A, Joannard F, Guillouzo A et al. Regulation of phenobarbital induction of the cytochrome P450 2b9/10 genes in primary mouse hepatocyte culture. Involvement of calcium- and cAMP-dependent pathways. Eur J Biochem 2000; 267 963-970.
45. Goodwin B, Moore JT. CAR: Detailing new models. Trends Pharmacol Sci 2004; 25: 437-441.
46. Aquino A, Hartman K, Knode M, Grant S, Huang K, Niu C et al. Role of protein kinase C in phosphorylation of vinculin in adriamycin-resistant HL-60 leukemic cells. Cancer Res 1988; 48 3324-3329.
47. Sugawara S, Kumano N, Saijo S, Numata Y, Sato G, Motomiya M. Protein kinase C activity in human leukemia cell lines with reference to sensitivity to antineoplastic agents. Tohoku J Exp Med 1992; 168: 393-396.
48. Kazanietz MG, Areces LB, Bahador A, Mischak H, Goodnight J, Mushinski JF et al. Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol 1993; 44: 298-307.
49. Jirtle RL, Meyer SA, Brockenbrough JS. Liver tumor promoter phenobarbital: A biphasic modulator of hepatocyte proliferation. Prog Clin Biol Res 1991; 369: 209-216.
50. Inoue K, Negishi M. Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J Biol Chem 2008; 283: 10425-10432.
51. Marchant JS, Subramanian VS, Parker I, Said HM. Intracellular trafficking and membrane targeting mechanisms of the human reduced folate carrier in mammalian epithelial cells. J Biol Chem 2002; 277: 33325-33333.
52. Kubitz R, Sdsutfels G, Kühlkamp T, Kölling R, Häussinger D. Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase. Gastroenterology 2004; 126: 541-553.
53. Westermann P, Knoblich M, Maier O, Lindschau C, Haller H. Protein kinase C bound to the Golgi apparatus supports the formation of constitutive transport vesicles. Biochem J 1996; 320: 651-658.
54. Radau B, Otto A, Müller EC, Westermann P. Protein kinase C alpha-dependent phosphorylation of Golgi proteins. Electrophoresis 2000; 21: 2684-2687.
55. Buccione R, Bannykh S, Santone I, Baldassarre M, Facchiano F, Bozzi Y et al. Regulation of constitutive exocytic transport by membrane receptors. A biochemical and morphometric study. J Biol Chem 1996; 271: 3523-3533.
56. Keenan C, Kelleher D. Protein kinase C and the cytoskeleton. Cell Signal 1998; 10: 225-232.